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Abstract
Background: The aim of this study was to evaluate the cost-effectiveness of CRC screening strategies from the
healthcare service provider perspective based on Chinese population.
Methods: A Markov model was constructed to compare the cost-effectiveness of recommended screening strategies
including annual/biennial guaiac fecal occult blood testing (G-FOBT), annual/biennial immunologic FOBT (I-FOBT), and
colonoscopy every 10 years in Chinese aged 50 year over a 25-year period. External validity of model was tested
against data retrieved from published randomized controlled trials of G-FOBT. Recourse use data collected from
Chinese subjects among staging of colorectal neoplasm were combined with published unit cost data ($USD in
2009 price values) to estimate a stage-specific cost per patient. Quality-adjusted life-years (QALYs) were quantified
based on the stage duration and SF-6D preference-based value of each stage. The cost-effectiveness outcome was the
incremental cost-effectiveness ratio (ICER) represented by costs per life-years (LY) and costs per QALYs gained.
Results: In base-case scenario, the non-dominated strategies were annual and biennial I-FOBT. Compared with no
screening, the ICER presented $20,542/LYs and $3155/QALYs gained for annual I-FOBT, and $19,838/LYs gained and
$2976/QALYs gained for biennial I-FOBT. The optimal screening strategy was annual I-FOBT that attained the highest
ICER at the threshold of $50,000 per LYs or QALYs gained.
Conclusion: The Markov model informed the health policymakers that I-FOBT every year may be the most effective
and cost-effective CRC screening strategy among recommended screening strategies, depending on the willingness-
to-pay of mass screening for Chinese population.
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Background
Accumulated evidence suggested that screening by fecal
occult blood test (FOBT) is effective in reducing annual
CRC incidence and annual mortality [1]. Colonoscopy
and flexible sigmoidoscopy are alternative strategies recom-
mended for CRC screening [2] whereas population-based
case–control studies in the US have shown consider-
able reduction in annual mortality from colonoscopy
screening [3, 4]. Ideally randomized controlled trial (RCT)
provides direct empirical evidence of comparative effective-
ness of CRC screening strategies. To capture such long-
term CRC risk, previous RCTs were designed to randomly
allocate subjects into regular FOBT screening group and
no screening group lasted for at least 10 years [5–9]. A
RCT of assessing the comparative effectiveness of one-
time colonoscopy and I-FOBT is on-going and expected to
be completed in 2021 [10]. To strike a balance between
costs and effectiveness incurred by CRC screening, cost-
effectiveness analysis (CEA) provides decision and justifica-
tion for efficient resource allocation under a fixed budget
constraint.
Cost-effectiveness modeling on the US population has
shown that annual FOBT plus 5-yearly sigmoidoscopy
under full compliance rate [11] and colonoscopy every
10 years [12] are the most cost-effective in terms of life
years (LYs) gain for an average-risk population. A study
on the Hong Kong population found that FOBTand colon-
oscopy had an incremental cost of US$6222 and US$7211
per life year gained compared to no screening, respectively
[13]. Modeling by Woo et al. suggested that Chinese
women from age 50 to 75 years by colonoscopy every
10 years compared to no screening had an incremental
cost of US$55545 per disability-adjusted life years
averted [14]. However, the National Centre for Clinical
Excellence (NICE) recommended that quality of life
measured by a valid preference-based measure of health
should be incorporated into the outcome measure of
effectiveness, to so called quality adjusted life years
(QALYs), in analysis of an medical intervention [15].
The QALYs is the outcome measure of effectiveness on
which to incorporate both morbidity and mortality of
patients. UK studies estimated the incremental cost of
biennial FOBT compared to no screening to be below
£3000 per QALYs, and thus biennial FOBT alone was
the most cost-effective screening strategy [16, 17]. The
optimal screening strategies in the USA and Canada be-
come colonoscopy every 10 years [18, 19]. However,
projected results of multiple studies may not be extrap-
olated to the Chinese population.
Although the CRC incidence rate of the Chinese popu-
lations is approaching those of developed countries [20],
there is no agreed policy on CRC screening for the
Chinese population in Hong Kong or mainland China.
No CEA of CRC screening in terms of QALYs gain has
ever been done on Chinese populations. Most CEA on
FOBT were based on G-FOBT, evaluation of the more
accurate but more expensive I-FOBT is warranted.
Therefore, the aim of paper was to evaluate the in-depth
cost-effectiveness analysis of colorectal cancer screening
strategies from the healthcare service provider perspec-
tive in Hong Kong, China. The specific objectives were
1) to determine the expected life years gained from the
reduction in the incidence and mortality rates of CRC
for each CRC screening strategy, 2) to determine the
QALY gained from each CRC strategy by combining the
preference value with life years gained, and 3) to identify
the most cost-effective CRC screening strategy and to
determine the incremental cost per additional QALY
gained compared to no screening, by Markov modeling.
Methods
Ethical approval was obtained from The University of
Hong Kong/Hospital Authority Hong Kong West Cluster
institutional review board (HKU/HA HKW IRB #UW
09–391), and this trial was registered with Hong Kong
Clinical Trial Register (#HKCTR-973).
Model overview
Six screening strategies for colorectal adenomas and
CRC were compared in cost and effectiveness under a
decision analytic model based on a state-transition Mar-
kov process [21]. A hypothetical static cohort of 100,000
persons from 50-year-old Hong Kong population entered
the model and their health histories were simulated by sex
until 75 years old. Under the model framework, each per-
son had an initial health state based on the distribution of
colorectal adenomas [22]. The natural history of colorectal
neoplasms (CRN) was reflected on the model via the tran-
sitions between different health states and the mortalities
(Fig. 1). Superimposed on the natural history were the
screening interventions and subsequent colonoscopic sur-
veillance after polyp removal or stage-specific treatment
upon the detection of a CRC.
Natural history
The key feature of the model was the health states of
CRN which were divided into four sections:
 the Pre-CRC section included “Normal colonic
epithelium”, “Low-risk polyps” and “High-risk polyps”;
 the Undiagnosed CRC section consisted of
“Undiagnosed Stage I CRC”, “Undiagnosed Stage II
CRC”, “Undiagnosed Stage III CRC” and “Undiagnosed
Stage IV CRC”;
 the Diagnosed CRC section was comprised of
“Diagnosed Stage I CRC”, “Diagnosed Stage II CRC”,
“Diagnosed Stage III CRC” and “Diagnosed Stage IV
CRC”;
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 the Death section was divided into “Death from
CRC”, “Death from screening complications” and
“Death from other causes”.
According to the screening surveillance guideline [23],
low-risk polyps are defined as ≤2 adenomas or 3–4 ad-
enomas which are < 1 cm while high-risk polyps are de-
fined as ≥5 adenomas or ≥3 adenomas of which at least
one is ≥ 1 cm. The health states of CRC were classified
by the American Joint Committee on Cancer staging
system [24].
All health states were modelled as Markov states with
1-year cycle. A person would transit to a different health
state or remain at its current health state at the end of
every 1-year period in the Markov process [21]. With dif-
ferent transition probabilities employed to link a health
state to the others, the model tried to capture the essence
of the natural history of CRN. All health states were at risk
to the progression to a more advanced disease stage or
death, but they were prohibited from returning to the
former health states except that low-risk and high-risk
polyps patients could recover and return to normal co-
lonic epithelium after polyp removal with polypectomy. It
was assumed that normal colonic epithelium and low-risk
polyps were at no risk of progression to CRC in a 1-year
cycle, the transition probability between normal colonic
epithelium and low-risk polyps was taken from a previous
study [16] which summarized the incidence rates of aden-
omas within the average risk population. The annual
probabilities that low-risk polyps develop into high-risk
polyps, or high-risks polyps develop into non-metastatic
CRC were taken from a cost-effectiveness analysis [25].
CRC patients could either be clinically undiagnosed or di-
agnosed. Undiagnosed CRC were at risk of progression to
more advanced stages of CRC and mortality from CRC or
other causes. Each year those CRC undiagnosed patients
had a certain probability of symptomatic presentation
[26], in which case they were assumed to consult a phys-
ician and to have the diagnosis confirmed by colonoscopy.
Another condition of CRC diagnosis was detection of the
malignancy by screening interventions. When they were
diagnosed to have CRC, they would receive specific as-
sessments and treatments according to disease stages. It
was assumed that the risk of disease progression was elim-
inated once the CRC was diagnosed and treated and they
would remain in the same health state but they were still
at risk of mortality from CRC or other causes.
The most severe health states were the three causes of
death, described as the absorbing stages in the terminology
of Markov processes [21]. Death from CRC meant dying
from clinical complications of CRC. The annual CRC mor-
talities by stage of disease were extracted from a Chinese
study which was based on the Hong Kong Cancer Registry
in 2007 [13]. There had been no mass CRC screening pro-
grammes in Hong Kong so it was valid to use the general
population CRC mortality data to represent the natural
history that was not modified by screening interventions.
Death from screening complications was specifically
formulated to reflect the risk of mortality from serious
complications of bleeding or perforation in endoscopic
Fig. 1 Annual Transition of health states in Markov Modelling
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procedures. However, mortalities from other complica-
tions (e.g. drug anaphylaxis) were not considered in this
model. Death from other causes mirrored the mortal-
ities from all possible causes apart from those related
to CRC and screening complications. The correspond-
ing annual mortality from causes other than CRC and
screening complications was estimated by the non-CRC
mortality, which was derived by subtracting the CRC
mortality by sex and quinqueenial age groups (e.g. 50–
54, 55–59, etc.) [27] from the all-cause mortality by sex
and age which was quoted from the Hong Kong Life
Table in 2007 [28]. The natural history parameters for
the model are shown in Additional file 1.
Screening strategies
The screening strategies were designed based on 3 core
screening interventions, i.e. G-FOBT, I-FOBT and colon-
oscopy, with different screening periods. Six commonly
used strategies were identified from a review of the US
national guidelines [2, 29], previous cost-effectiveness
analysis studies [16, 30], population-based screening pro-
grammes [6–8, 31–35] and local studies [36]. Among
them, 5 were single-intervention strategies, and a no
screening strategy functioned as a control. The repeated
period of screening is 1 or 2 year (s) for G-FOBT/I-FOBT,
and 10 years for colonoscopy. The strategies were listed
below:
i. no screening
ii. annual G-FOBT (Hemoccult-II SENSA, Beckman
Coulter, Inc., California, USA)
iii. annual I-FOBT (actim Fecal Blood, Medix Biochemica,
Finland)
iv. biennial G-FOBT (Hemoccult-II SENSA, Beckman
Coulter, Inc., California, USA)
v. biennial I-FOBT (actim Fecal Blood, Medix Bio-
chemica, Finland)
ix. ix. colonoscopy every 10 years
With the one-sample per screening round, people who
had positive G-FOBT or qualitative I-FOBT result were
assumed to proceed immediately to a colonoscopy to
confirm the result. Polypectomy would be undertaken
once any polyp was found on colonoscopy. After polyp
removal, a surveillance colonoscopy was assigned to the
patient every 5 years if the polyp was of low-risk and
every 1 year if of high-risk. If CRC rather than polyp was
detected, the patient transacted to a CRC state and re-
ceived specific assessment and treatment according to
the disease stage of CRC.
Diagnostic performance of the screening tests
The performance of the screening tests was deter-
mined by the sensitivities and specificities in detecting
adenomatous polyps and cancers. Sensitivities and speci-
ficities associated with G-FOBT and I-FOBT were based
on the results of two local Hong Kong studies [22, 37].
The sensitivity and specificity associated with colonoscopy
were assumed to be 100 % although there were no re-
search data on the true accuracy of colonoscopy [38].
When accessing the diagnostic performance of a screening
test, it is important to take into account the possible
serious complications. This consideration is irrelevant
to G-FOBT and I-FOBT as these are no complications
associated with those tests. For colonoscopy, the major
severe complications are bleeding and perforation. The
probabilities of bleeding and perforation for colonos-
copy as well as the mortalities from these complications
were estimated from the data of several overseas studies
since local data were not available [39–46]. Additional
file 1 shows the performance characteristics of the G-FOBT,
I-FOBT and colonoscopy.
Screening participation
Screening interventions assigned to a person are not
mandatory. One has the right to refused attending a
screening even if it was scheduled with free of charge.
This important fact affects the ‘efficacy’ of a screening
intervention significantly. Our model first assumed that
a person had a constant probability to participate in any
kind of screening intervention each time it was assigned
to the person, independent of the individual’s past history
of participation in screening or surveillance for CRC. A
constant compliance rate of 60 % was assumed for all
screening interventions involved in the 6 screening strat-
egies in the base-case scenario [11]. For the follow-up col-
onoscopy after positive test result in the initial screening
or the surveillance colonoscopy after polyp removal or
CRC diagnosis, a high compliance rate of 80 % was as-
sumed [11]. For those patients who had symptomatic
presentation of CRC, it was assumed a full compliance
on the colonoscopy screening arrangement after physician
consultation, and the patient withdrew from the screening
strategy originally arranged. Additional file 1 shows the
compliance rate on G-FOBT, I-FOBTand colonoscopy.
Model validation
External validity of our model was accessed by comparing
the model outcomes with the study results from published
clinical studies which were anticipated to be consistent
with the model findings [47]. The cohort size and patient
characteristics were modified to replicate that of the popu-
lation or sample of the data source applied. Our model
was initiated by obtaining similar outcome measures as
the published data so that head-to-head comparisons were
made. One criterion of CRC mortality rate reduction
was assessed under this framework. Taking the ratio of
CRC mortality rates, the reduction in mortality rate of
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a screening strategy from the other competing strategies
was calculated. The reduction in CRC mortality for G-
FOBT reported by randomized controlled trials [5, 7, 8]
was compared with our model results (Additional file 1).
The reductions for colonoscopy reported by case–control
studies [3, 4, 48] were incomparable with our model re-
sults for colonoscopy every 10 years because the previous
studies reported irregular screening interval for repeated
colonoscopy.
Additional file 1 shows a comparison of model-
anticipated CRC mortality rates reduction compared with
equivalent previous studies estimate. Our Markov model
appeared to provide excellent fit of CRC mortality reduc-
tion by biennial G-FOBT against results from Funen trial
data [7] whilst the model reported a reasonable fit against
reduction in CRC mortality reported with Nottingham
and Minnesota screening trials [5, 8]. Comparison indi-
cated an acceptable model validity of predicting the reduc-
tion in CRC mortality from annual and biennial G-FOBT.
Model outcomes
Costs outcomes
The perspective of health service provider was adopted
when evaluating the costs for the CRN care, so only dir-
ect medical costs were incorporated to the model. The
costs were divided into three groups according to the
period of the diagnosis of CRN: Pre-diagnosis, First year
of diagnosis, and Subsequent years of diagnosis. Costs of
cancer care were primarily allocated to the initial phase
(first year of diagnosis) as well as the continuing and
terminal phases (subsequent years of diagnosis) of care
after the diagnosis of CRC. Costs for the terminal phase
of care were assumed to be priced in the same way as the
continuing phase. In the pre-diagnosis phase, only screen-
ing of CRN contributed to the costs but the treatment
was included. The stage-specific costs for CRN care were
derived from the usage data of the relevant screening tests
though the modeling. Costs for the initial phase of care
were extracted from a Hong Kong study [49] which sum-
marized the local direct medical costs for each health state
of CRN, while that for the subsequent years of diagnosis
were drawn from the guideline of polyps surveillance after
polyps removal [23] and the cancer treatment protocol on
the recommended use of medical services following surgi-
cal operation [50]. Unit costs estimates associated with
the screening tests and the outpatient follow-up in special-
ist clinics (including basic investigation tests such as Chest
X-rays and laboratory tests) were based on the published
data from the Government Gazette [51]. The costs of the
screening complications were derived from a previous
cost-effectiveness analysis modeled on Chinese population
[13]. Local costs evaluated in Hong Kong dollar (year
2009 values) were converted to US dollar at the pegged
exchange rate of USD 1 = HKD 7.8. Unit costs of the
service components and the stage-specific costs of ini-
tial care are shown in Additional file 1. Direct medical
costs of care related to CRN were accumulated for each
cycle over the screening period of 25 years. The tech-
nique of half-cycle correlation was applied to give more
accurate measures of the costs [21]. The lifetime medical
costs per person for all screening strategies were the out-
come of cost measure. All the costs were discounted by
an annual rate of 3.5 % as recommended by the guidance
of NICE [15].
Effectiveness outcomes
Two effectiveness outcomes were assessed by the Markov
model: the LYs and QALYs. The life expectancy of each
cohort under a particular screening strategy was calcu-
lated. The QALYs are generated by adjusting the LYs
according to a preference-based measure of health-related
quality of life. The LYs and QALYs gained of a screening
strategy from the other was computed by taking the dif-
ference of the life expectancies and quality-adjusted life
expectancies of the two strategies, respectively.
Utility scores of each health state of the CRN patients
defined in our model was associated with a constant utility
score, representing “death” of 0 and “perfect health” of 1.
Provided that the scoring algorithm for utility score is
culture-specific, we adopted the utility input from an
existing scoring algorithm developed based on local
population. To date, Chinese version of SF-6D with the
Hong Kong Chinese population based scoring algorithm
[52, 53] made available to compute the SF-6D utility
scores whilst scoring algorithms for other utility metrics
such as EQ-5D did not. Moreover, the SF-6D score was
shown to be responsive to change in Hong Kong Chinese
population [54]. Hence, the estimates of the stage-specific
utility scores were adopted from a study [55]. People who
had normal colorectal epithelium were assumed to have
perfect health with utility score of 1 [18]. Half-cycle
correlation was used again for the measures of LYs and
QALYs [21], and they were discounted as the same rate
as the costs, i.e. 3.5 % annually [15].
Cost-effectiveness analysis
Core outcome of the cost-effectiveness analysis was the
incremental cost-effectiveness ratio (ICER) which was
calculated by dividing the incremental cost (ΔC) by the
incremental effectiveness (ΔE) in terms of LYs or QALYs
gained for a particular screening strategy compared to other
less effective screening strategy. The cost-effectiveness ana-
lysis was executed by the comparison of the ICER values of
different screening strategies.
The dominated and extended dominated strategies were
reported on the figures [56]. By definition, the strategy is
dominated if it is less effective and most expensive than
one of the competing strategies. The strategy is regarded
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as extended dominance if it is less effective and had a
higher ICER than one of the competing strategies. The
line connecting the strategies which were not dominance
and extended dominance formed the efficiency frontier
[57]. The ICER values of any two adjacent strategies on
the efficiency frontier were determined. For a given ceiling
ratio of λ, which is the maximum amount of willingness-
to-pay per effectiveness gain [58], the optimal strategy was
defined as the one with the highest ICER value below λ,
compared to the next less effective strategy on the effi-
ciency frontier. Accumulative In current study, the ceiling
ratio was defined at a threshold of US$50,000 per effect-
iveness gained [19, 59–63].
Sensitivity analysis
Deterministic (univariate and multivariate) and probabilis-
tic sensitivity analysis (PrSA) were performed to explore
the stochasticity and uncertainty on the model parameters
and outputs. Univariate sensitivity analysis for the ICER of
any two non-dominated strategies on the efficiency fron-
tiers was conducted on the major screening based variables
which included compliance rates of screening, follow-up
and surveillance colonoscopy and performance characteris-
tic of each screening strategy. In addition, the utilities of
the different health states, the disease stage-specific treat-
ment costs, the transition probabilities, the CRC mortal-
ities, the probabilities of symptomatic presentation, and
annual discount rate were also included in the analysis.
The cut-off values used in the univariate sensitivity analysis
were the minimum and maximum values extracted from
the literature. In case no such information was available,
95 % confidence limits or values suggested by clinical
experts were used. Multivariate sensitivity analysis varied
difference sets of utility scores for health states reported in
previous models [16, 19, 64].
PrSA was conducted finally to achieve a full examin-
ation of the uncertainty involved in the model parameters
and consequently the model outputs. All the parameters
except the time horizon and the discount rate were associ-
ated with a probability distribution. A Monte Carlo
simulation was carried out to randomly draw from those
distributions for 10,000 iterations. CRC Mortality rate
from cancer registry were excluded from the PrSA as par-
ameter uncertainty is small. The probability distributions
with associated distribution parameters are displayed in
Additional file 1. Cost parameters were assigned to be log-
normally distributed whilst probability, rate and utility pa-
rameters were assigned to beta-distribution [65]. The cost
and effectiveness (in QALYs or LYs) for a strategy com-
pared to no screening were computed for the 10,000 itera-
tions. The cost-effectiveness acceptability curve [57] was
then constructed to demonstrate the probability of being
cost-effective for each strategy in the 10,000 iterations at
each level of the ceiling ratio.
The main computational tool we used to perform the
cost-effectiveness analysis was TreeAge Pro Suite 2009
Release 1.0.2 (TreeAge Software, Inc., Williamstown, MA,
US). The Microsoft Excel 2010 was used for supplemen-
tary analysis and graphical production.
Results
Base-case scenario
Table 1 shows the incremental cost of a screening strategy
from the other competing strategies, ranked in the as-
cending order of effectiveness. With additional work-up
due to screening, every screening intervention was more
expensive than no screening. The most expensive strategy
was annual G-FOBT costing $2853 more compared to no
screening. Apart from no screening, the cheapest strategy
was biennial G-FOBT which costs $1681 more than no
screening. Annual FOBT screening did cost more than
colonoscopy and biennial FOBT screening. By convention,
every CRC screening strategy extended life expectancy
and quality adjusted life expectancy. Annual I-FOBT was
the most effective CRC screening strategy, in which
provided 0.12305 LYs and 0.80121 QALYs compared to
no screening. Colonoscopy every 10 years gained more
life expectancies than the biennial G-FOBT while col-
onoscopy every 10 years averted more quality adjusted
Table 1 Cost, LYs and QALYs per person for each screening strategy, and the incremental cost, LYs and QALYs of a screening
strategy compared with no screening








Cost ($USD) per person 2541 4221 5394 4752 4542 5068
Incremental cost (ΔC, $) compared with no screening - 1681 2853 2212 2001 2528
Expected LYs per person 15.6420 15.6862 15.7104 15.7385 15.7429 15.7650
Incremental LYs compared with no screening - 0.0443 0.0684 0.0965 0.1009 0.1231
Expected QALYs per person 14.7479 15.0687 15.2339 15.3586 15.4203 15.5491
Incremental QALYs compared with no screening - 0.3207 0.4860 0.6106 0.6724 0.8012
Note: G-FOBT, Guaiac fecal occult blood testing; I-FOBT, immunologic fecal occult blood testing
aSort by ascending order of effectiveness
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life expectancies than biennial G-FOBT over a simulated
period of 25 years.
Table 2 shows the incremental cost-effectiveness ratio
in term of cost per LYs and cost per QALYs of a screening
strategy from the other competing strategies, respectively.
The plots of the cost-effectiveness plane against the two
effectiveness measures of LYs and QALYs respectively for
all the six screening strategies are presented in Fig. 2.
Taking account of life expectancy only and quality of
life adjustment, biennial G-FOBT was extended domi-
nated because it was slightly less effective than biennial
I-FOBT, and had higher ICER ($37,985/LYs vs $19,838/
LYs; $5240/QALYs vs $2976/QALYs) than biennial I-FOBT
relative to no screening. Strategies of colonoscopy every
10 years and annual G-FOBT were dominated with lower
effectiveness and higher costs. All I-FOBT screening
remained more effective and cost-effective than colonos-
copy and G-FOBT screening.
The ICERs for annual I-FOBT, colonoscopy every
10 years and annual G-FOBT presented $24,608/QALYs,
$3155/QALYs, $3622/QALYs and $5871/QALYs gained
when competing with no screening respectively. Hence,
the ICERs were far below from the willingness-to-pay
threshold of approximately $50,000/QALYs gained.
Table 3 gives the ranges of λ which the optimal strategy
varies from one range to another competing strategy.
Biennial I-FOBT was the optimal screening strategy for
a range of $19,838-$23,742/LYs ($2976-$4087/QALYs)
whilst annual I-FOBT was the optimal strategy in threshold
of more than $23,742/LYs or $4087/QALYs. Default no
screening would be the most optimal screening strategy for
CRC in the range of ceiling ratio between zero and
$19,838/LYs (or $2976/QALYs). As a consequence, annual
I-FOBT was the optimal strategy with an ICER closet to
$50,000 per LYs as well as per QALYs.
Table 2 The ICER in terms of $/LYs or $/QALYs of a Screening Strategy from the Other Competing Strategies
Strategya ICER Biennial G-FOBT Annual G-FOBT Colonoscopy every 10 years Biennial I-FOBT Annual I-FOBT
No Screening $/LYs 37,985 41,688 22,913 19,838 20,542
$/QALYs 5240 5871 3622 2976 3155
Biennial G-FOBT $/LYs 48,461 10,154 5657 10,747
$/QALYs 7096 1831 911 1763
Annual G-FOBT $/LYs Dominanceb Dominanceb Dominanceb
$/QALYs
Colonoscopy every 10 years $/LYs Dominanceb 11,916
$/QALYs 1659
Biennial I-FOBT $/LYs 23,742
$/QALYs 4087
Note: G-FOBT, Guaiac fecal occult blood testing; I-FOBT, immunologic fecal occult blood testing; ICER, Incremental cost-effectiveness ratio
aSort by ascending order of effectiveness
bAnnual G-FOBT was dominated by colonoscopy every 10 years and I-FOBT every 1 or 2 year(s) whereas colonoscopy every 10 years was dominated by
biennial I-FOBT
Fig. 2 Cost-effectiveness Plane for all the Six Screening Strategies
using LYs (Upper) and QALYs (Lower) as Effectiveness Outcome
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Sensitivity analysis
Results of the one-way sensitivity analysis for ICER for
the comparisons amongst annual I-FOBT, biennial I-FOBT
and no screening were described below. The most sensitive
collection of clinical parameters was the natural history pa-
rameters representing the annual transition probabilities
between health states. Varying unit costs in resource used
in care of CRN and utility scores for health state had
limited impact on the cost-effectiveness comparing
amongst non-dominated strategies. However, the spe-
cificity of I-FOBT was the most influential parameter
when annual I-FOBT was compared with biennial FOBT.
Decreased specificity of I-FOBT was associated with an
increased in ICER for annual I-FOBT compared with
biennial I-FOBT.
Figure 3 shows the results of PrSA using the cost-
effectiveness acceptability curve. Results demonstrated that
no strategy had a probability to be optimal higher than
60 % at a ceiling ratio of $50,000 per LY gained. Given a
maximum acceptable ceiling ratio of $7000 per QALY
gained, the probability that annual I-FOBT is cost-effective
compared with other screening strategies exceeded 70 %
but the probability that colonoscopy every 10 years is
cost-effective was about 20 %. The probability of annual
I-FOBT and colonoscopy every 10 years being cost-
effective converged to 75 and 25 %, respective, if the
maximum acceptable ceiling ratio increased to $50,000
per QALY gained.
Discussion
The present paper demonstrated the cost-effectiveness
of CRC screening using Chinese data on evaluating the
most cost-effective strategy based on two cost-effectiveness
outcomes, cost per LYs and QALYs gained. The model
compared six strategies for CRC screening currently imple-
mented by population-based screening programmes, and
recommended by international guidelines and previous
studies. The fact that no uniform screening strategies is cur-
rently implemented in healthcare provider setting in Hong
Kong and mainland China unleashes the comparative cost-
effectiveness of no screening relative to other screening
strategies in Chinese populations. In this model, no screen-
ing interventions exceeded the threshold of US$50,000/
QALYs gained. Given the low ICER for every screening
intervention, additional benefits provided by CRC screening
appears to be cost-effective compared to no screening in
case when the greater willingness-to-pay for screening was
possessed by health policymakers. The cost-effective plane
provided the judgment that annual G-FOBT and colonos-
copy every 10 years were dominated by I-FOBT screening,
irrespective of annual or biennial repeated period. Either
one of I-FOBT screenings was more cost-effective than all
competing screening strategies for a given ceiling ratio of
more than US$19,838/LYs or US$2976/QALYs gained. In
other words, no screening was favorable compared to CRC
screening at a ceiling ratio of not more than US$19,838/LYs
or US$2976/QALYs gained. The annual I-FOBT screening
Table 3 Optimal strategy according to the Ceiling Ratio in Base-case and Multivariate Scenarios
Optimal Strategy
Ceiling Ratio No Screening Biennial G-FOBT Annual G-FOBT Colonoscopy every 10 years Biennial I-FOBT Annual I-FOBT
In term of LYs
Base-case scenario
[0, 19,838] Extended Dominance Dominance Dominance (19,838, 23,742] (23,742, +∞)
Non-discounted Scenario (Discount Rate = 0 %)
[0, 14,681] Extended Dominance Dominance Dominance (14,681, 15,856] (15,856, +∞)
In term of QALYs
Base-case scenario
[0, 2976] Extended Dominance Dominance Dominance (2976, 4087] (4087, +∞)
Non-discounted Scenario (Discount Rate = 0 %)
[0, 2510] Extended Dominance Dominance Dominance (2510, 3294] (3294, +∞)
Ramsey’s Utility Set Scenario (Cancer free = 1.00; S1/S2 = 0.90; S3 = 0.80; S4 = 0.76)
[0, 12,294] Extended Dominance Dominance Dominance (12,294, 15,279] (15,279, +∞)
Ness’s Utility Set Scenario (Cancer free = 0.91; S1 = 0.74; S2 = 0.70; S3 = 0.50; S4 = 0.25)
[0, 9278] Extended Dominance Dominance Dominance (9278, 11,803] (11,803, +∞)
Sharp’s Utility Set Scenario (Cancer free = 0.94; S1/S2/S3/S4 = 0.80)
[0, 12,505] Extended Dominance Dominance Dominance (12,505, 15,460] (15,460, +∞)
Note: G-FOBT, Guaiac fecal occult blood testing; I-FOBT, immunologic fecal occult blood testing; ∞, infinity
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was found to be preferable for a ceiling ratio of US$23,742/
LYs or US$4087/QALYs gained.
The model provided evidence that the I-FOBT screen-
ing strategy, with superiority in sensitivity and specifi-
city, was more cost-effective than G-FOBT, which was in
line with the majority of modeling studies comparing be-
tween guaiac and immunologic testing, as indicated by
the US [12, 63] and other countries [18, 66, 67]. Consid-
ering the differences between screening strategies under
the same screening interval, the annual I-FOBT domi-
nated the annual G-FOBT. Alternatively, the biennial
G-FOBT was extended dominance by colonoscopy
every 10 years, which was discordant with the recent
Australian and French studies [68, 69] comparing be-
tween these two strategies, concluding that biennial G-
FOBT was more cost-effective than colonoscopy every
10 years. However, in earlier Australian reports [70, 71],
the ICER for colonoscopy was lower than that for biennial
G-FOBT, indicating the extended dominance of G-FOBT.
To our knowledge, six models were built with the utility
input for health states. Three models [16, 18, 60, 72] ob-
tained the health preference scores for each CRC health
states from a study [73] on the basis of direct elicitation
using a standard gamble exercise, while the others [19, 64]
used the health preference scores for each CRC stage
estimated from Health Utility Index Mark III (HUI3) in-
strument. The QALYs calculation based on SF-6D utility
scores [55] was a special feature of this model, instead of
conventional input of utility estimates elicited from con-
ventional direct valuation methods or measured by HUI3.
In addition, utility scores for non-CRC (or cancer free)
health states were not assumed to be one in a majority of
past models [16, 19, 64, 72], specifying at value ranging
from 0.90 to 0.94 while the rest of models assumed the
non-cancer states to be full health with a utility score
being one [18, 60]. However, utility scores for non-CRC
states (diversified to normal colonic epithelium, low-risk
polyp, and high-risk polyp) were no longer assumed to be
Fig. 3 Cost-effectiveness Acceptability Curve (CEAC) in term of LYs (Upper) and QALYs (Lower) for all Strategies in Probabilistic Sensitivity Analysis
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identical in current study while same utility scores had as-
sumed for both undiagnosed and diagnosed colorectal
polyps or CRC [16, 18, 19, 60, 64, 72]. The differentials of
cost per QALYs gained were partly explained by the con-
siderable differences in the data source with respect to
utility scores for relevant health states.
The consideration of screening strategy has been lim-
ited to single strategy, instead of the hybrid strategy with
the combination of I-FOBT with colonoscopy or flexible
sigmoidoscopy. Theoretically, the hybrid strategy that ad-
vocates the complementary implementation of annual
I-FOBT and colonoscopy every 10 years is the most effect-
ive strategy relative to all competing strategies adopted in
current study, but the complicated administration and
delivery of such screening strategy is not executed in an
underway large randomized controlled trial [10] that was
assigned to either one-time colonoscopy or biennial
I-FOBT. Challenges still remained in overcoming the
practical concerns over the logistic delivery of hybrid
strategy in real world situation.
Several limitations with respect to the model assump-
tions should be noted. First, our results were primarily
simulated by Markov modeling. We assumed that the
disease progression and cost spending were the same in
the tumour locations of colon and rectum. It is believed
that the incidence and mortality rates for colon cancer
were overall greater than those for rectal cancer but the
direct medical expenditures for colon cancer were cheaper
than those for rectal cancer. Adjustment for tumour site
could yield simulation results in a more precise way.
Second, the utility data was measured by cross-sectional
study rather than randomized controlled trial with suffi-
cient follow-up periods, which involves the consideration
of time-dependent utility data in the short and long term.
This health economic evaluation has informed the cli-
nicians and policy makers that I-FOBT every one or two
years emerged as the most effective and cost-effective
colorectal cancer screening strategy compared with no
screening in Chinese population. The uncertainty analysis
surrounding the major parameters supported the cost-
effectiveness analysis derived from base-case scenario.
Strategies that utilized colonoscopy alone and annual
G-FOBT alone were dominated by other currently rec-
ommended strategies for population-based screening.
The findings were generalizable to Chinese population,
as the cost and clinical parameters input were mostly
based on Chinese data. Despite no reaching consensus,
such conclusion recommended the inclusion of I-FOBT
to the guidelines on colorectal cancer screening for
Chinese population.
Conclusion
The Markov model informed the health policymakers that
I-FOBT every year may be the most effective and
cost-effective CRC screening strategy among recommended
screening strategies, depending on the willingness-to-pay of
mass screening for Chinese population.
Additional file
Additional file 1: Appendix A. Natural History Parameters, Performance
Characteristics and Compliance Rate of the G-FOBT, I-FOBT and Colonoscopy
Used in Markov Model. Appendix B. Model Validation Results. Appendix C.
Costs Parameters and Utility Scores by Stage of Colorectal Neoplasms Used in
the Markov Model. Appendix D. Cut-off values Used in the Univariate
Sensitivity Analysis and Probability Distributions with Associated Distribution
Parameters of Model Parameters Used in Probabilistic Sensitivity Analysis.
(DOCX 91 kb)
Abbreviations
CRC: Colorectal cancer; CEA: Cost-effectiveness analysis; G-FOBT: Guaiac fecal
occult blood testing; I-FOBT: Immunologic fecal occult blood testing;
QALYs: Quality-adjusted life-years; ICER: Incremental cost-effectiveness ratio;
LY: Life-years; RCT: Randomized controlled trial; CRN: Colorectal neoplasms;
NICE: National Centre for Clinical Excellence; PrSA: Probabilistic sensitivity
analysis; HUI3: Health Utility Index Mark III.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design, acquisition of data, analysis and interpretation of
data, drafting of the manuscript, administrative, technical, material support:
CKHW and CLKL. Analysis and interpretation of data, statistical analysis:
CKHW and EYFW. Critical revision of the manuscript for important intellectual
content, CKHW, CLKL, EYFW and DYTF. All authors read and approved the
final manuscript.
Acknowledgement
Funding for this study was provided by Small Project Funding (Project code
200907176135) from CRCG of The University of Hong Kong, and Health and
Health Service Research Fund (HHSRF #08090851) of Food and Health Bureau,
HKSAR. The authors would like to express the graduate towards Vincent Ma for
his valuable input in the earlier stage of model development.
Author details
1Department of Family Medicine and Primary Care, The University of Hong
Kong, 3/F, Ap Lei Chau Clinic, 161 Ap Lei Chau Main Street, Ap Lei Chau,
Hong Kong, Hong Kong. 2School of Nursing, The University of Hong Kong,
Hong Kong, Hong Kong.
Received: 28 March 2014 Accepted: 8 October 2015
References
1. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al.
Long-Term Mortality after Screening for Colorectal Cancer. N Engl J Med.
2013;369(12):1106–14.
2. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM.
American College of Gastroenterology Guidelines for Colorectal Cancer
Screening 2008. Am J Gastroenterol. 2009;104(3):739–50.
3. Muller AD, Sonnenberg A. Protection by Endoscopy Against Death From
Colorectal Cancer: A Case–control Study Among Veterans. Arch Intern Med.
1995;155(16):1741–8.
4. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L.
Association of Colonoscopy and Death From Colorectal Cancer. Ann Intern
Med. 2009;150(1):1–8.
5. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, et al. The
Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer.
N Engl J Med. 2000;343(22):1603–7.
6. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal Cancer Mortality:
Effectiveness of Biennial Screening for Fecal Occult Blood. J Natl Cancer Inst.
1999;91(5):434–7.
Wong et al. BMC Cancer  (2015) 15:705 Page 10 of 12
7. Kronborg O, Fenger C, Olsen J, Jørgensen OD, Søndergaard O. Randomised
study of screening for colorectal cancer with faecal-occult-blood test.
Lancet. 1996;348(9040):1467–71.
8. Hardcastle JD, Chamberlain JO, Robinson MHE, Moss SM, Amar SS, Balfour
TW, et al. Randomised controlled trial of faecal-occult-blood screening for
colorectal cancer. Lancet. 1996;348(9040):1472–7.
9. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al.
Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult
Blood. N Engl J Med. 1993;328(19):1365–71.
10. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, et al.
Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer
Screening. N Engl J Med. 2012;366(8):697–706.
11. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of Screening
for Colorectal Cancer in the General Population. JAMA. 2000;284(15):1954–61.
12. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen
M, Kuntz KM. Evaluating Test Strategies for Colorectal Cancer Screening: A
Decision Analysis for the U.S. Preventive Services Task Force. Ann Intern
Med. 2008;149(9):659–69.
13. Tsoi KKF, Ng SSM, Leung MCM, Sung JJY. Cost-effectiveness analysis on
screening for colorectal neoplasm and management of colorectal cancer in
Asia. Aliment Pharmacol Ther. 2008;28(3):353–63.
14. Woo PP, Kim JJ, Leung GM, Woo PPS, Kim JJ, Leung GM. What is the most
cost-effective population-based cancer screening program for Chinese
women? J Clin Oncol. 2007;25(6):617–24.
15. National Institute for Clinical Excellence. Guide to the Methods of
Technology Appraisal (reference N1618). London: NICE; 2008.
16. Tappenden P, Chilcott J, Eggington S, Sakai H, Karnon J, Patnick J. Option
appraisal of population-based colorectal cancer screening programmes in
England. Gut. 2007;56(5):677–84.
17. Whynes DK, Neilson AR, Walker AR, Hardcastle JD. Faecal occult blood
screening for colorectal cancer: is it cost-effective? Health Econ. 1998;7(1):21–9.
18. Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA. The cost-effectiveness of
screening for colorectal cancer. CMAJ. 2010;182(12):1307–13.
19. Sharaf RN, Ladabaum U. Comparative Effectiveness and Cost-Effectiveness of
Screening Colonoscopy vs. Sigmoidoscopy and Alternative Strategies. Am J
Gastroenterol. 2013;108(1):120–32.
20. Sung JJY, Lau JYW, Goh KL, Leung WK. Increasing incidence of colorectal
cancer in Asia: implications for screening. Lancet Oncol. 2005;6(11):871–6.
21. Sonnenberg FA, Beck JR. Markov Models in Medical Decision Making: A
Practical Guide. Med Decis Mak. 1993;13(4):322–38.
22. Sung JJY, Chan FKL, Leung WK, Wu JCY, Lau JYW, Ching J, et al. Screening for
colorectal cancer in Chinese: Comparison of fecal occult blood test, flexible
sigmoidoscopy, and colonoscopy. Gastroenterology. 2003;124(3):608–14.
23. Atkin WS, Saunders BP. Surveillance guidelines after removal of colorectal
adenomatous polyps. Gut. 2002;51 suppl 5:v6–9.
24. Greene FL, Page DL, Fleming ID, Balch CM, Haller DG, Morrow M. AJCC
Cancer Staging Manual. 6th ed. New York: Springer Publishers; 2002.
25. Leshno M, Halpern Z, Arber N. Cost-Effectiveness of Colorectal Cancer Screening
in the Average Risk Population. Health Care Manag Sci. 2003;6(3):165–74.
26. SEER Cancer Statistics Review, 1975–2007 [http://seer.cancer.gov/csr/1975_2007/].
Accessed 28 March 2014.
27. Hong Kong Cancer Registry Web Site [http://www.ha.org.hk/cancereg].
Accessed 28 March 2014.
28. Hong Kong Census and Statistics Department. Projected Hong Kong life
tables, 2007–2036. Hong Kong: Government Printers; 2007.
29. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S.
Preventive Services Task Force Recommendation Statement. Ann Intern
Med. 2008;149(9):627–37.
30. Macafee DAL, Waller M, Whynes DK, Moss S, Scholefield JH. Population
screening for colorectal cancer: the implications of an ageing population. Br
J Cancer. 2008;99(12):1991–2000.
31. Lisi D, Hassan CC, Crespi M. Participation in colorectal cancer screening with
FOBT and colonoscopy: An Italian, multicentre, randomized population
study. Dig Liver Dis. 2010;42(5):371–6.
32. Hol L, Van Leerdam ME, Van Ballegooijen M, Van Vuuren AJ, Van Dekken H,
Reijerink JCIY, et al. Screening for colorectal cancer: randomised trial
comparing guaiac-based and immunochemical faecal occult blood testing
and flexible sigmoidoscopy. Gut. 2010;59(01):62–8.
33. Goulard H, Boussac-Zarebska M, Ancelle-Park R, Bloch J. French colorectal
cancer screening pilot programme: results of the first round. J Med Screen.
2008;15(3):143–8.
34. Weller D, Moss S, Butler P, Campbell C, Coleman D, Melia J, et al. English
Pilot of Bowel Cancer Screening: an evaluation of the second round. Final
Report to the Department of Health. London: Institute of Cancer Research;
2006.
35. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Long-Term
Efficacy of Sigmoidoscopy in the Reduction of Colorectal Cancer Incidence.
J Natl Cancer Inst. 2003;95(8):622–5.
36. Wong BC, Chan AO, Wong KW, Ching CK, Wong WM, Tam S, et al. A pilot
study of participation in faecal occult blood testing and screening colonoscopy
after health education in Hong Kong. Eur J Cancer Prev. 2005;14(2):181–4.
37. Wong WM, Lam SK, Cheung KL, Tong TSM, Rozen P, Young GP, et al. Evaluation
of an automated immunochemical fecal occult blood test for colorectal
neoplasia detection in a Chinese population. Cancer. 2003;97(10):2420–4.
38. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for Colorectal Cancer: A
Targeted, Updated Systematic Review for the U.S. Preventive Services Task
Force. Ann Intern Med. 2008;149(9):638–58.
39. Macrae FA, Tan KG, Williams CB. Towards safer colonoscopy: a report on
the complications of 5000 diagnostic or therapeutic colonoscopies. Gut.
1983;24(5):376–83.
40. Levin TR, Conell C, Shapiro JA, Chazan SG, Nadel MR, Selby JV. Complications
of screening flexible sigmoidoscopy. Gastroenterology. 2002;123(6):1786–92.
41. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, et al. Baseline
Findings of the Italian Multicenter Randomized Controlled Trial of “Once-Only
Sigmoidoscopy”–SCORE. J Natl Cancer Inst. 2002;94(23):1763–72.
42. Nelson DB, McQuaid KR, Bond JH, Lieberman DA, Weiss DG, Johnston TK.
Procedural success and complications of large-scale screening colonoscopy.
Gastrointest Endosc. 2002;55(3):307–14.
43. Gatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk
of Perforation After Colonoscopy and Sigmoidoscopy: A Population-Based
Study. J Natl Cancer Inst. 2003;95(3):230–6.
44. Levin TR, Zhao W, Conell C, Seeff LC, Manninen DL, Shapiro JA, et al.
Complications of Colonoscopy in an Integrated Health Care Delivery
System. Ann Intern Med. 2006;145(12):880–6.
45. Rathgaber SW, Wick TM. Colonoscopy completion and complication rates in
a community gastroenterology practice. Gastrointest Endosc. 2006;64(4):556–62.
46. Ko CW, Riffle S, Shapiro JA, Saunders MD, Lee SD, Tung BY, et al. Incidence
of minor complications and time lost from normal activities after screening
or surveillance colonoscopy. Gastrointest Endosc. 2007;65(4):648–56.
47. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe
C, et al. Principles of Good Practice for Decision Analytic Modeling in
Health-Care Evaluation: Report of the ISPOR Task Force on Good Research
Practices—Modeling Studies. Value Health. 2003;6(1):9–17.
48. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection
From Colorectal Cancer After Colonoscopy: A Population-Based, Case–Control
Study. Ann Intern Med. 2011;154(1):22–30.
49. Wong CKH, Lam CLK, Poon JTC, McGhee SM, Law WL, Kwong DLW, et al.
Direct Medical Costs of Care for Chinese Patients with Colorectal
Neoplasia: a Health Care Service Provider Perspective. J Eval Clin Pract.
2012;18(6):1203–10.
50. Cheng KC, Yeung YP, Lau PYY, Meng WCS. Surveillance and outcome of
liver metastasis in patients with colorectal cancer who had undergone
curative-intent operation. Hong Kong Med J. 2008;14(6):432–6.
51. Hospital Authority. List of charges: S.S. No. 4 to Gazette No. 44/1996 and G.N.
2028 to Gazette No. 13/2003. Hong Kong: Hong Kong Government Printers;
1996, 2003.
52. Lam CLK, Brazier J, McGhee SM. Valuation of the SF-6D Health States Is
Feasible, Acceptable, Reliable, and Valid in a Chinese Population. Value
Health. 2008;11(2):295–303.
53. McGhee SM, Brazier J, Lam CLK, Wong LC, Chau J, Cheung A, et al. Quality-
adjusted life years: population-specific measurement of the quality component.
Hong Kong Med J. 2011;17 Suppl 6:17–21.
54. Wong CKH, Mulhern B, Wan Y-F, Lam CLK. Responsiveness was similar
between direct and mapped SF-6D in colorectal cancer patients who
declined. J Clin Epidemiol. 2014;67(2):219–27.
55. Wong CKH, Lam CLK, Poon JTC, Kwong DLW. Clinical Correlates of Health
Preference and Generic Health-related Quality of Life in Patients with
Colorectal Neoplasms. PLoS One. 2013;8(3):e58341.
56. Cantor SB. Cost - Effectiveness Analysis, Extended Dominance, and Ethics.
Med Decis Mak. 1994;14(3):259–65.
57. Barton GR, Briggs AH, Fenwick EAL. Optimal Cost-Effectiveness Decisions:
The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-
Wong et al. BMC Cancer  (2015) 15:705 Page 11 of 12
Effectiveness Acceptability Frontier (CEAF), and the Expected Value of
Perfection Information (EVPI). Value Health. 2008;11(5):886–97.
58. Stinnett AA, Mullahy J. Net Health Benefits: a new framework for the analysis of
uncertainty in cost-effectiveness analysis. Med Decis Mak. 1998;18(2):S68–80.
59. Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I,
Habbema JDF, van Ballegooijen M. How much colonoscopy screening
should be recommended to individuals with various degrees of family
history of colorectal cancer? Cancer. 2011;117(18):4166–74.
60. Dan YY, Chuah BYS, Koh DCS, Yeoh KG. Screening Based on Risk for
Colorectal Cancer Is the Most Cost-Effective Approach. Clin Gastroenterol
Hepatol. 2012;10(3):266–271.e266.
61. Vijan S, Hwang I, Inadomi J, Wong RKH, Choi JR, Napierkowski J, et al. The
Cost-Effectiveness of CT Colonography in Screening for Colorectal
Neoplasia. Am J Gastroenterol. 2007;102(2):380–90.
62. Ladabaum U, Phillips KA. Colorectal Cancer Screening: Differential Costs for
Younger Versus Older Americans. Am J Prev Med. 2006;30(5):378–84.
63. Song K, Fendrick AM, Ladabaum U. Fecal DNA testing compared with
conventional colorectal cancer screening methods: a decision analysis.
Gastroenterology. 2004;126(5):1270–9.
64. Sharp L, Tilson L, Whyte S, O’Ceilleachair A, Walsh C, Usher C, et al. Cost-
effectiveness of population-based screening for colorectal cancer: a
comparison of guaiac-based faecal occult blood testing, faecal
immunochemical testing and flexible sigmoidoscopy. Br J Cancer.
2012;106(5):805–16.
65. Briggs AH. Handling Uncertainty in Cost-Effectiveness Models.
PharmacoEconomics. 2000;17(5):479–500.
66. Berchi C, Bouvier V, Réaud J-M, Launoy G. Cost-effectiveness analysis of two
strategies for mass screening for colorectal cancer in France. Health Econ.
2004;13(3):227–38.
67. van Rossum LGM, van Rijn AF, Verbeek ALM, van Oijen MGH, Laheij RJF,
Fockens P, et al. Colorectal cancer screening comparing no screening,
immunochemical and guaiac fecal occult blood tests: A cost-effectiveness
analysis. Int J Cancer. 2011;128(8):1908–17.
68. Lejeune C, Dancourt V, Arveux P, Bonithon-Kopp C, Faivre J. Cost-effectiveness
of screening for colorectal cancer in France using a guaiac test versus an
immunochemical test. Int J Technol Assess Health Care. 2010;26(01):40–7.
69. Pignone MP, Flitcroft KL, Howard K, Trevena LJ, Salkeld GP, John DJBS. Costs
and cost-effectiveness of full implementation of a biennial faecal occult blood
test screening program for bowel cancer in Australia. MJA. 2011;194(4):180–5.
70. O’Leary BA, Olynyk JK, Neville AM, Platell CF. Cost-effectiveness of colorectal
cancer screening: Comparison of community-based flexible sigmoidoscopy
with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol.
2004;19(1):38–47.
71. Graves N, McKinnon L, Leggett B, Newman B. Re-interpreting the data on
the cost and effectiveness of population screening for colorectal cancer in
Australia. Aust New Zealand Health Policy. 2005;2(1):10.
72. Heitman SJ, Hilsden RJ, Au F, Dowden S, Manns BJ. Colorectal cancer
screening for average-risk North Americans: an economic evaluation.
PLoS Med. 2010;7(11):e1000370.
73. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states
of colorectal cancer. Am J Gastroenterol. 1999;94(6):1650–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wong et al. BMC Cancer  (2015) 15:705 Page 12 of 12
